https://scholars.lib.ntu.edu.tw/handle/123456789/543781
標題: | Primary primitive neuroectodermal tumor of the urinary tract | 作者: | KUO-HOW HUANG CHIA-TUNG SHUN Huang S.-Y. HONG-JENG YU SHIH-CHIEH CHUEH Chen J. |
公開日期: | 2006 | 出版社: | Scientific Communications International Ltd | 卷: | 105 | 期: | 12 | 起(迄)頁: | 1008-1012 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Primary primitive neuroectodermal tumor (PNET) of urinary tract is a rare disease with aggressive behavior and poor prognosis. We analyzed 851 cases of urinary tract malignancies in our hospital between 1984 and 2004. Only three (0.035%) cases with PNET of the urinary tract were identified. Presenting symptoms included flank pain and hematuria. The first case was a 44-year-old man with left renal PNET who underwent hand-assisted laparoscopic radical nephrectomy and adjuvant chemotherapy. There was no recurrent tumor at the 4-year follow-up. The second case was a 75-year-old woman with fight renal PNET with inferior vena cava (IVC) thrombosis extending to the right atrium. The patient underwent fight radical nephroureterectomy and IVC thrombectomy with cardiopulmonary bypass. She died of metastatic disease 7 months later. The third case was a 45-year-old man with left ureteral PNET. Left ureteral segmental resection and partial cystectomy were performed. Tumor recurrence was noted 7 years later. The patient died of disseminated disease 1 year after the discovery of recurrence. Urinary tract PNET appears to be an aggressive malignancy. Long-term survival if complete resection is performed at an early stage. ? 2006 Elsevier & Formosan Medical Association. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33846320055&doi=10.1016%2fS0929-6646%2809%2960285-0&partnerID=40&md5=5fe8e09036cf0b04ab18cd4bf720d935 https://scholars.lib.ntu.edu.tw/handle/123456789/543781 |
ISSN: | 0929-6646 | DOI: | 10.1016/S0929-6646(09)60285-0 | SDG/關鍵字: | CD99 antigen; cyclophosphamide; docetaxel; doxorubicin; etoposide; ifosfamide; imatinib; mesna; neuron specific enolase; protein S 100; topotecan; transcription factor Fli 1; vincristine; adjuvant therapy; adult; aged; article; cancer adjuvant therapy; cancer mortality; cancer palliative therapy; cancer radiotherapy; cancer recurrence; cancer staging; cancer survival; case report; cavography; clinical feature; combination chemotherapy; computer assisted tomography; cystectomy; cystoscopy; disseminated cancer; female; flank pain; follow up; hematuria; histopathology; human; immunohistochemistry; inferior cava vein; laparoscopic surgery; laser surgery; male; metastasis; multiple cycle treatment; nephrectomy; nephroureterectomy; neuroectoderm tumor; nuclear magnetic resonance imaging; prognosis; thrombectomy; transurethral resection; ureteroneocystostomy; urinary tract cancer; vein thrombosis |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。